Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -2.91% | |
| Outside Day | Range Expansion | -2.91% | |
| Narrow Range Bar | Range Contraction | -1.57% | |
| Inside Day | Range Contraction | -1.57% | |
| Down 3 Days in a Row | Weakness | -1.57% | |
| Fell Below 20 DMA | Bearish | -2.53% | |
| Bearish Engulfing | Bearish | -3.85% | |
| Up 3 Days in a Row | Strength | -8.09% | |
| Gapped Down | Weakness | -8.09% | |
| Inside Day | Range Contraction | -7.41% |
| Alert | Time |
|---|---|
| Down 3% | about 24 hours ago |
| Fell Below Previous Day's Low | about 24 hours ago |
| Down 2 % | about 24 hours ago |
| Down 1% | about 24 hours ago |
| 20 DMA Resistance | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/14/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.17 |
| 52 Week Low | 2.0902 |
| Average Volume | 207,751 |
| 200-Day Moving Average | 4.84 |
| 50-Day Moving Average | 5.76 |
| 20-Day Moving Average | 5.19 |
| 10-Day Moving Average | 5.19 |
| Average True Range | 0.36 |
| RSI (14) | 43.50 |
| ADX | 12.56 |
| +DI | 24.15 |
| -DI | 21.97 |
| Chandelier Exit (Long, 3 ATRs) | 4.88 |
| Chandelier Exit (Short, 3 ATRs) | 5.47 |
| Upper Bollinger Bands | 5.76 |
| Lower Bollinger Band | 4.61 |
| Percent B (%b) | 0.34 |
| BandWidth | 22.28 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.18 |
| MACD Histogram | 0.0375 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.38 | ||||
| Resistance 3 (R3) | 5.38 | 5.27 | 5.31 | ||
| Resistance 2 (R2) | 5.27 | 5.17 | 5.26 | 5.29 | |
| Resistance 1 (R1) | 5.13 | 5.11 | 5.08 | 5.13 | 5.27 |
| Pivot Point | 5.02 | 5.02 | 4.99 | 5.01 | 5.02 |
| Support 1 (S1) | 4.88 | 4.92 | 4.83 | 4.88 | 4.73 |
| Support 2 (S2) | 4.77 | 4.86 | 4.76 | 4.71 | |
| Support 3 (S3) | 4.63 | 4.77 | 4.69 | ||
| Support 4 (S4) | 4.63 |
